Learning from “Elite” Responders to Develop Better Immunotherapies
Release Date:
A subset of patients treated with checkpoint inhibitors respond particularly well to these immunotherapies. These so-called “elite responders” produce antibodies that modulate immune cells in the tumor microenvironment. OncoResponse is working to discover the antibodies these elite responders produce to develop a pipeline of cancer therapies. We spoke to Bob Lechleider, chief medical officer of OncoRepsonse, about the tumor microenvironment, how his company is studying elite responders to immunotherapies to discover new antibodies to modulate the immune system, and his company’s lead program in clinical development.
Learning from “Elite” Responders to Develop Better Immunotherapies